BOSTON, Mass. (TheStreet) -- Here is June's calendar of important, potentially stock-moving biotech events:

May 29-June 3

The American Urological Association annual meeting.

June 2

FDA advisory panel meets to review


(AZN) - Get Report

Numax for respiratory syncytial virus.

June 3

BioDelivery Sciences

(BDSI) - Get Report

analyst/investor meeting.

Johnson & Johnson

(JNJ) - Get Report

analyst/investors meeting.

June 4-8


American Society of Clinical Oncology (ASCO) annual meeting. Data

presentation expected from

Celldex Therapeutics

(CLDX) - Get Report



(ZIOP) - Get Report


Delcath Systems




(PFE) - Get Report



(CELG) - Get Report

-- and too many other companies to mention here.

June 4

Cell Therapeutics

(CTIC) - Get Report

annual shareholder meeting.

June 10

FDA advisory panel meets to review


(NVS) - Get Report

oral multiple sclerosis drug Gilenia. FDA's briefing materials should be posted to the agency's web site on June 8. The Gilenia panel is also important for

Biogen Idec

(BIIB) - Get Report



(TEVA) - Get Report

TST Recommends



, which market current injectable MS drugs.

June 10-13

European Hematological Association meeting.

June 11

FDA approval decision date for

Questcor Pharmaceuticals'


Acthar Gel for infantile spasms.

June 16


( GENZ) annual shareholder meeting.

June 16-19

European League Against Rheumatism meeting. Lupus data presentations from

Human Genome Sciences

( HGSI) and




(IMMU) - Get Report


International Society for Stem Cell Research meeting.

June 18

FDA advisory panel meets to review

Boehringer Ingelheim's

filbanserin for the treatment of female sexual dysfunction. The filbanserin panel could also impact

Biosante Pharmaceuticals


and its competing female libido drug LibiGel, currently in phase III studies.

June 24

FDA approval decision date for AstraZeneca's Numax for respiratory syncytial virus.

Ligand Pharmaceuticals

(LGND) - Get Report

analyst/investor day.

June 25-29

American Diabetes Association annual meeting.

Sometime in June

Phase III study results from



anemia drug Hematide.

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on



Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;

click here

to send him an email.